Immediate liver function testing is required if symptoms of liver injury appear: nausea and vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, yellowing of the skin or sclera, right upper abdominal pain, etc. If liver injury is confirmed, medication should be suspended and regular follow‑up examinations performed. Once liver function recovers to Grade 1 or below, treatment may be resumed at the original dose or an adjusted dose (160 mg, 80 mg).
Continuous monitoring is required after resuming treatment. Permanent discontinuation is necessary if Grade 2 or 3 liver injury recurs. The safety of this medicine in patients with moderate to severe hepatic impairment has not been established, and its use is not recommended in such patients. Special reminder: This medicine carries a risk of convulsions. During treatment, patients should avoid engaging in activities such as working at heights or driving that may cause danger due to sudden loss of consciousness. If a convulsion occurs during treatment, the medicine must be permanently discontinued immediately.
